Disease Domain | Count |
---|---|
Neoplasms | 11 |
Endocrinology and Metabolic Disease | 2 |
Top 5 Drug Type | Count |
---|---|
Antibody drug conjugate (ADC) | 8 |
Small molecule drug | 2 |
Immune stimulating antibody conjugate (ISAC) | 1 |
Target |
Mechanism NaPi-2b inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HER2 modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism B7-H4 inhibitors [+4] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date08 Feb 2023 |
Sponsor / Collaborator |
Start Date24 Jan 2023 |
Sponsor / Collaborator |
Start Date20 Jan 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Upifitamab Rilsodotin ( NaPi-2b x Tubulin ) | Fallopian Tube Carcinoma More | Phase 3 |
XMT-2056 ( HER2 x STING ) | HER2-positive gastric cancer More | Phase 1 |
XMT-1660 ( B7-H4 x Tubulin ) | Ovarian Cancer More | Phase 1 |
XMT-2175 ( STING ) | Neoplasms More | Preclinical |
XMT-2068 ( STING ) | Neoplasms More | Preclinical |